Personalis, Inc. PSNL stock is up in Tuesday’s premarket session after the company received Medicare coverage for its NeXT ...

Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostic company pioneering the field of molecular cytology, today announced the launch of its Percepta™ Bronchial Genomic Classifier, a new genomic test ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company’s NeXT Personal molecular residual disease (MRD) test for ...

FOSTER CITY, Calif., April 28, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary ...

Understanding those genetic “errors” has become central to modern lung cancer care. Biomarker testing, sometimes called ...

Yale researchers recently discovered new genes that could be used to test potential treatment options for a rare form of aggressive lung cancer. Each year, about 6,000 Americans — roughly 3 percent of ...

Mar. 23 -- SATURDAY, June 2 (HealthDay News) -- U.S. researchers say they've developed new tests that can determine the precise genetic pathways that lead to lung cancer. Being able to examine these ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

Is the Galleri multi-cancer blood test worth it? A doctor explains real-world performance data and explains why no major ...

Low-dose CT scan helps detect lung cancer early, improving survival. Learn who needs LDCT screening, its benefits, risks and how it saves lives.